| scholarly article | Q13442814 |
| P50 | author | Stuart C. Ray | Q7626381 |
| Ramy El-Diwany | Q56883476 | ||
| Madeleine C Mankowski | Q58208041 | ||
| Valerie J Kinchen | Q88497172 | ||
| Justin R Bailey | Q96257761 | ||
| Lisa N Wasilewski | Q125310332 | ||
| Jillian K Brady | Q125310360 | ||
| P2093 | author name string | Ben Murrell | |
| Anna E Snider | |||
| William O Osburn | |||
| P2860 | cites work | Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. | Q22010245 |
| MEGA6: Molecular Evolutionary Genetics Analysis version 6.0 | Q24498082 | ||
| MUSCLE: multiple sequence alignment with high accuracy and high throughput | Q24613456 | ||
| Identification of Conserved Residues in the E2 Envelope Glycoprotein of the Hepatitis C Virus That Are Critical for CD81 Binding | Q27477468 | ||
| Viral Sequence Evolution in Acute Hepatitis C Virus Infection | Q27484985 | ||
| CD8 Epitope Escape and Reversion in Acute HCV Infection | Q27485189 | ||
| Cellular immune selection with hepatitis C virus persistence in humans | Q27485219 | ||
| Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses | Q27485952 | ||
| Mutations in Hepatitis C Virus E2 Located outside the CD81 Binding Sites Lead to Escape from Broadly Neutralizing Antibodies but Compromise Virus Infectivity | Q27488430 | ||
| Identification and Characterization of Broadly Neutralizing Human Monoclonal Antibodies Directed against the E2 Envelope Glycoprotein of Hepatitis C Virus | Q27490467 | ||
| Hepatitis C Virus E2 Envelope Glycoprotein Core Structure | Q27680704 | ||
| Glycan shifting on hepatitis C virus (HCV) E2 glycoprotein is a mechanism for escape from broadly neutralizing antibodies | Q27684112 | ||
| The rapid generation of mutation data matrices from protein sequences | Q27860880 | ||
| Genetic diversity and evolution of hepatitis C virus--15 years on | Q29547888 | ||
| Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence | Q29616009 | ||
| Genetic Heterogeneity of Hepatitis C Virus: Quasispecies and Genotypes | Q29619748 | ||
| The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
| A Hepatitis C Virus Envelope Polymorphism Confers Resistance to Neutralization by Polyclonal Sera and Broadly Neutralizing Monoclonal Antibodies | Q30383939 | ||
| Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses | Q33707246 | ||
| Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection | Q33853655 | ||
| Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein | Q33913588 | ||
| Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus | Q33955998 | ||
| The natural history of hepatitis C virus infection: host, viral, and environmental factors | Q33974693 | ||
| Prospective evaluation of community-acquired acute-phase hepatitis C virus infection | Q33986385 | ||
| Humoral immune response in acute hepatitis C virus infection | Q33989160 | ||
| Non-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412-423 | Q34047477 | ||
| Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus | Q34228030 | ||
| Community Outbreak of HIV Infection Linked to Injection Drug Use of Oxymorphone--Indiana, 2015. | Q34474460 | ||
| Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization | Q34594986 | ||
| Broadly neutralizing antibodies abrogate established hepatitis C virus infection | Q35032263 | ||
| Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance | Q35242585 | ||
| Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations | Q35274913 | ||
| Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion | Q35741969 | ||
| Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein | Q36506935 | ||
| Broad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV Infection | Q36811958 | ||
| CD81-receptor associations--impact for hepatitis C virus entry and antiviral therapies. | Q37611842 | ||
| Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies | Q37629584 | ||
| Current progress in development of hepatitis C virus vaccines. | Q38120201 | ||
| The mechanism of HCV entry into host cells | Q38321419 | ||
| Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step | Q38335402 | ||
| A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance. | Q38809451 | ||
| Generation and Characterization of Monoclonal Antibodies against a Cyclic Variant of Hepatitis C Virus E2 Epitope 412-422. | Q39062848 | ||
| Antibody Response to Hypervariable Region 1 Interferes with Broadly Neutralizing Antibodies to Hepatitis C Virus | Q39602767 | ||
| Increases in hepatitis C virus infection related to injection drug use among persons aged ≤30 years - Kentucky, Tennessee, Virginia, and West Virginia, 2006-2012. | Q40278327 | ||
| Acceleration of hepatitis C virus envelope evolution in humans is consistent with progressive humoral immune selection during the transition from acute to chronic infection | Q40341996 | ||
| Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication-competent virus and pseudoparticles | Q40527984 | ||
| Detection of a sexually transmitted hepatitis C virus protease inhibitor-resistance variant in a human immunodeficiency virus-infected homosexual man. | Q42213859 | ||
| Hepatitis C in the United States | Q42992102 | ||
| Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group | Q42993140 | ||
| Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge | Q43048336 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P921 | main subject | hepatitis C | Q154869 |
| Hepatitis C virus | Q708693 | ||
| P304 | page(s) | e1006235 | |
| P577 | publication date | 2017-02-24 | |
| P1433 | published in | PLOS Pathogens | Q283209 |
| P1476 | title | Extra-epitopic hepatitis C virus polymorphisms confer resistance to broadly neutralizing antibodies by modulating binding to scavenger receptor B1 | |
| P478 | volume | 13 |
| Q92964702 | A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor |
| Q59351582 | Approaches, Progress, and Challenges to Hepatitis C Vaccine Development |
| Q91862927 | Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2 |
| Q59349176 | Can Broadly Neutralizing Monoclonal Antibodies Lead to a Hepatitis C Virus Vaccine? |
| Q90134557 | Clearance of hepatitis C virus is associated with early and potent but narrowly-directed, Envelope-specific antibodies |
| Q56395915 | Defining Breadth of Hepatitis C Virus Neutralization |
| Q47548062 | Designing a B Cell-Based Vaccine against a Highly Variable Hepatitis C Virus |
| Q99407917 | Global and local envelope protein dynamics of hepatitis C virus determine broad antibody sensitivity |
| Q65002126 | Hepatitis C Virus Genetic Variability, Human Immune Response, and Genome Polymorphisms: Which Is the Interplay? |
| Q59349677 | Hepatitis C virus escape studies for human antibody AR3A reveals a high barrier to resistance and novel insights on viral antibody evasion mechanisms |
| Q59354660 | Hepatitis C virus escape studies for human monoclonal antibody AR4A reveal isolate-specific resistance and a high barrier to resistance |
| Q57490859 | Hypervariable Region 1 in Envelope Protein 2 of Hepatitis C Virus: A Linchpin in Neutralizing Antibody Evasion and Viral Entry |
| Q63729516 | Hypervariable region 1 and N-linked glycans of hepatitis C regulate virion neutralization by modulating envelope conformations |
| Q64065756 | Identifying immunologically-vulnerable regions of the HCV E2 glycoprotein and broadly neutralizing antibodies that target them |
| Q55282191 | Mapping Determinants of Virus Neutralization and Viral Escape for Rational Design of a Hepatitis C Virus Vaccine. |
| Q92592914 | Plasma deconvolution identifies broadly neutralizing antibodies associated with hepatitis C virus clearance |
| Q55657826 | Predicting the Effectiveness of Hepatitis C Virus Neutralizing Antibodies by Bioinformatic Analysis of Conserved Epitope Residues Using Public Sequence Data. |
| Q40088796 | Structure-Based Design of Hepatitis C Virus Vaccines that Elicit Neutralizing Antibody Responses to a Conserved Epitope |
| Q47236942 | Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms. |
Search more.